Regeneron, Mammoth Launch $100M In Vivo CRISPR Collaboration for Multiple Diseases

Apr 25, 2024, 02:50 PM

Regeneron Pharmaceuticals has entered into a collaboration with Mammoth Biosciences to research, develop, and commercialize in vivo CRISPR-based gene editing therapies aimed at multiple diseases and tissues beyond the liver. The partnership involves a $100 million total upfront payment and equity investment by Regeneron, which includes $5 million upfront and a $95 million equity investment. This collaboration marks a significant expansion of Regeneron's efforts in genetic medicine, building on previous partnerships and acquisitions, including a longstanding research pact with Intellia Therapeutics for transthyretin amyloidosis and the purchase of a gene therapy biotech. The therapies will utilize Mammoth Biosciences’ ultracompact CRISPR and Regeneron's antibody-directed AAVs.